AZD1390
oral ATM kinase inhibitor Ph. I candidate oncology biochem-based screen. and BBB penetration opt J Pharmacol Exp Ther, Oct 1, 2022 AstraZeneca, Cambridge, UK
Molecules of the Month - September 2022
3 minute read
Oct. 29, 2022
AZD1390: a Brain-Penetrating Ataxia-Telangiectasia Mutated (ATM) Kinase Inhibitor